Heart Disease News and Research

Latest Heart Disease News and Research

New clinical guideline adopts holistic approach to brain and heart health

A new brain–heart clinical practice guideline takes a holistic approach, integrating neurologic and mental health evidence with guidance for cardiovascular disease as many brain and heart conditions overlap and share similar risk factors.

30 Mar 2026

Taking a placebo knowingly still improves stress and memory

Research indicates open-label placebos can ease stress and boost memory in older adults, presenting a novel, ethical strategy for promoting healthy aging.

30 Mar 2026

Short bursts of vigorous activity can lower risk of major diseases

People who get just a few minutes of vigorous activity daily are less likely to develop eight major diseases, including arthritis, heart disease and dementia, according to research published in the European Heart Journal today (Monday).

29 Mar 2026

Deferring PCI before TAVR shows comparable outcomes in elderly patients

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable outcomes regardless of whether they underwent percutaneous coronary intervention (PCI) before TAVR, according to findings from the PRO-TAVI study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Transcatheter valve-in-valve procedure improves short-term outcomes in high-risk patients

In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within one year, compared with patients who underwent standard repeat mitral valve replacement surgery, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Minimally invasive valve repair lowers hospitalizations in heart failure patients

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received optimal medical therapy plus a minimally invasive procedure using a clip to repair the valve were significantly less likely to die, have a heart attack or stroke and 40% less likely to be hospitalized for heart failure compared with similar patients who were randomly assigned to optimal medical therapy alone.

29 Mar 2026

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Noninvasive lung impedance monitoring improves outcomes in HFpEF patients

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with preserved ejection fraction (HFpEF), according to research presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Left-ventricular unloading during angioplasty fails to improve patient outcomes

The first randomized trial to compare standard percutaneous coronary intervention (PCI), also known as coronary angioplasty, with PCI accompanied by the use of a temporary, miniaturized pump to support the heart in patients with both severe coronary heart disease and moderate to severe heart failure found no significant difference between the two approaches.

29 Mar 2026

Novel vFFR method performs similar to invasive coronary assessment

A novel, minimally invasive method of determining whether fatty deposits in a coronary artery are restricting blood flow to a patient's heart performed similarly to the standard, more-invasive procedure in a large multi-country European randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

AI-based tool matches standard method for coronary blood flow assessment

A novel, minimally invasive computer software-based method that uses artificial intelligence to determine whether plaques in a coronary artery are restricting blood flow to the patient's heart performed similarly to the standard, more invasive wire-based procedure, according to a large international randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Angioplasty improves symptoms in chronic total coronary occlusion patients

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the artery showed statistically significant reductions in chest pain and improvements in quality of life compared with patients who received a placebo procedure.

29 Mar 2026

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Home-delivered DASH diet improves blood pressure and cholesterol outcomes

Black adults with high blood pressure who received dietitian counseling and home deliveries of groceries aligned with the DASH diet—meaning high in fruits, vegetables, whole grains, low-fat dairy, nuts, seeds, legumes and lean proteins—had an average overall reduction in systolic blood pressure of 7 mm Hg at three months overall and a 5 mm Hg reduction compared with participants who received only basic dietary guidance and a grocery stipend, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits

The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

Hypercortisolism found in many patients with resistant hypertension

The MOMENTUM study found 27 percent of patients with resistant hypertension have hypercortisolism. This is a significant finding, demonstrating that hypercortisolism is more common in these patients than previously understood by researchers and clinicians.

28 Mar 2026

Microaxial flow pump fails to reduce heart damage in STEMI trial

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage.

28 Mar 2026